Horizon Therapeutics has opened its new office in South San Francisco, CA, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions.
 
“This is a significant step as we continue to grow our manufacturing and R&D capability to address patient needs through the development of groundbreaking therapies,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We are excited to join the thriving life sciences community of South San Francisco, allowing us the opportunity to connect to newer technologies, leading academic institutions and the dynamic scientific area at large.”
 
Srini Ramanathan, vice president, development sciences and site head for the South San Francisco, Horizon, said, “This new facility will allow us to function more seamlessly and efficiently as we expand our pipeline. We look forward to exploring new partnerships in the South San Francisco biotech hub, and tapping into the wealth of talent in the area’s biotech and academic communities, as we develop new solutions to address needs in rare diseases and beyond.”
 
Horizon plans to add new positions in bioanalysis, clinical research, pharmacology, manufacturing and business development during the next year.